Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Graft Polymer (UK) PLC ( (GB:SVNS) ) has shared an update.
Solvonis Therapeutics plc has been featured in an article on ThisIsMoney.co.uk, highlighting its recent acquisition of Awakn Life Sciences and the integration of its development pipeline. The article discusses Solvonis’ lead programme, SVN-001, which is in Phase III clinical trials for severe Alcohol Use Disorder (AUD) in the UK and EU, and its second programme, SVN-002, targeting the US AUD market. The coverage also notes sector valuation comparisons and strategic interest in novel mental health therapeutics, underscoring Solvonis’ positioning in the industry.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company based in London and listed on the London Stock Exchange. The company focuses on developing novel medicines for addiction and mental health disorders, particularly targeting high-burden neuropsychiatric conditions such as Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD). Solvonis is advancing a pipeline of repurposed and novel compounds, with its lead asset, SVN-001, in Phase 3 trials for severe AUD in Europe and the UK. The company also has a preclinical PTSD programme and is expanding its R&D pipeline with an AI-supported discovery platform.
Average Trading Volume: 95,987,195
Technical Sentiment Signal: Buy
Current Market Cap: £23.17M
For detailed information about SVNS stock, go to TipRanks’ Stock Analysis page.